Good
Mostly Aligned
Patient Risk:
Low
Summary
The mechanism-of-action and antibody-class claims are largely supported by Sections 11 and 12.1. Several comparative classification claims about PD-L1 and CTLA-4 inhibitors extend beyond the supplied label, and the claim that Opdivo is used across multiple cancer types is not supported by the provided Indications and Usage text.
Category Scores
Accurate Statements
Opdivo (nivolumab) is a cancer immunotherapy in the class of programmed death 1 (PD-1) inhibitors.
Section 11 identifies nivolumab as a PD-1 blocking antibody, and Section 12.1 describes release of PD-1 pathway-mediated inhibition of the anti-tumor immune response.
Opdivo is a monoclonal antibody.
Section 12.1 describes nivolumab as a human IgG4 monoclonal antibody.
Opdivo blocks the PD-1 pathway.
Section 12.1 states that nivolumab binds to PD-1 and blocks interaction with PD-L1 and PD-L2.
Blocking the PD-1 pathway can help the immune system recognize and attack cancer cells.
Section 12.1 states that PD-1 blockade releases inhibition of the immune response, including the anti-tumor immune response.
Opdivo binds to PD-1 on T cells.
Section 12.1 identifies PD-1 as a receptor found on T cells and states that nivolumab binds to the PD-1 receptor.
Opdivo interferes with signals that normally reduce immune activity.
Section 12.1 states that PD-L1 and PD-L2 binding to PD-1 inhibits T-cell proliferation and cytokine production and that nivolumab blocks this interaction.
Opdivo can increase T-cell responses against tumors.
Section 12.1 supports release of PD-1 pathway-mediated inhibition of the anti-tumor immune response. The statement is appropriately framed as possible rather than guaranteed.
Opdivo is an immunotherapy and a PD-1 checkpoint inhibitor.
Sections 11 and 12.1 describe nivolumab as a PD-1 blocking antibody that releases inhibition of the immune response, including the anti-tumor immune response.
Unsupported Statements
Opdivo is used across multiple cancer types.
The supplied Section 1 Indications and Usage contains no text establishing approved uses across multiple cancer types.
Opdivo is not chemotherapy.
The supplied label sections describe nivolumab as a monoclonal antibody and PD-1 blocking agent but do not expressly state that it is not chemotherapy.
PD-L1 inhibitors are immune checkpoint inhibitors in a similar target family to Opdivo but bind a different partner.
Section 12.1 identifies PD-L1 as a ligand for PD-1 but does not describe PD-L1 inhibitors, classify them as immune checkpoint inhibitors, or establish the stated target-family relationship.
CTLA-4 inhibitors are immune checkpoint inhibitors directed at another checkpoint target.
Section 12.1 refers to ipilimumab as an anti-CTLA-4 antibody and describes CTLA-4 blockade, but does not expressly provide the broader classification used in the claim.
PD-L1 inhibitors and CTLA-4 inhibitors are grouped with Opdivo by mechanism rather than being the same exact drug class.
Section 12.1 distinguishes PD-1 and CTLA-4 blockade and identifies PD-L1 as a PD-1 ligand, but does not discuss the claimed drug-class taxonomy for PD-L1 and CTLA-4 inhibitors.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The claims are primarily descriptive mechanism and classification statements and do not provide dosing, treatment instructions, or safety advice. The unsupported claims could cause minor classification or indication confusion but do not directly contradict the supplied label or instruct unsafe use.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Aligned
Primary Issue
Several claims about approved cancer types and the classification of PD-L1 and CTLA-4 inhibitors are not established by the supplied label sections.
Suggested Improvement
Limit the explanation to the label-supported mechanism: nivolumab is an IgG4 monoclonal antibody that binds PD-1 and blocks interaction with PD-L1 and PD-L2. Avoid asserting multiple approved cancer types or broader checkpoint-inhibitor taxonomy unless the relevant label sections are supplied.